BPMC(Delisted)
Blueprint Medicines (BPMC) Stock Statistics, Valuation & Financial Metrics
Total Valuation
Blueprint Medicines market cap is -- and enterprise value is --.
Share Statistics
Blueprint Medicines has 64.58M shares outstanding, with a free float of 62.35M.
Valuation Ratios
Blueprint Medicines's PE ratio is --, PB ratio is --, and PS ratio is --, showing whether the stock looks expensive or cheap.
Solvency
Blueprint Medicines debt-to-equity ratio is -- and debt-to-assets ratio is 0.71.
Liquidity
Blueprint Medicines's current ratio is 2.8, quick ratio is 2.75, and cash ratio is --, showing its short-term liquidity position.
Return on Capital
Blueprint Medicines's ROE is --, ROA is --, and ROIC is --, showing its return on capital profile.
Profitability
Blueprint Medicines gross margin is 96.48%, operating margin is -31.01%, and net margin is -27.70%.
Cost Structure
Blueprint Medicines spends 61.40% of revenue on R&D and 66.09% on SG&A.
Operating Efficiency
Blueprint Medicines's asset turnover is --, inventory turnover is --, and receivables turnover is --, indicating its operating efficiency.
Income Statement
Blueprint Medicines's revenue is 562.12M, gross profit is 542.35M, net income is --, and EBITDA is --.
Balance Sheet
Blueprint Medicines's total debt is --, net debt is --, total equity is --, and cash is --.
Cash Flow Statement
Blueprint Medicines's operating cash flow is -145.55M, free cash flow is -150.91M, and CapEx is -5.36M.
Dividends & Yields
Blueprint Medicines dividend yield is --, with a payout ratio of -- and dividend per share of --.
Analyst Rating
Blueprint Medicines's latest analyst rating is Unrate, with an analyst target price of --.
Company Info
A global precision therapy company that invents life-changing therapies for people with cancer and blood disorders
Per Share Metrics
Blueprint Medicines's EPS is --, book value per share is --, and free cash flow per share is --.
